.
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.
phil lempert: it's affordability. it's convenience. it's not having a lot of waste. people are more concerned about waste than ever before.
.